Trials / Unknown
UnknownNCT05645601
CAR-NK Targeted CD19 for r/r B-cell Malignancies
Early Clinical Study of Allogenic CAR-NK Targeted CD19 (JD010) in the Treatment of Adult Relapsed or Refractory B-cell Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies. JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19-CAR-NK | The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy. |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-05-30
- Completion
- 2024-12-30
- First posted
- 2022-12-09
- Last updated
- 2022-12-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05645601. Inclusion in this directory is not an endorsement.